Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Kulke, Matthew H ^a   Bendell, Johanna ^b   Kvols, Larry ^c   Picus, Joel ^d   Pommier, Rodney ^e   Yao, James ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d USA   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHLOROZOTOCIN; DACARBAZINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; TEMOZOLOMIDE; THALIDOMIDE; VASCULOTROPIN RECEPTOR 1; ANTINEOPLASTIC AGENT;

CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; GLUCAGONOMA; HUMAN; INSULIN BLOOD LEVEL; INSULINOMA; LIVER METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; REVIEW; SURGICAL TECHNIQUE; VIPOMA; VON HIPPEL LINDAU DISEASE; ZOLLINGER ELLISON SYNDROME;

ANTINEOPLASTIC AGENTS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 79958278279     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-29     Document Type: Review

References (67)

1. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. DC Metz RT Jensen, Gastroenterology 2008 135 1469 1492 10.1053/j.gastro.2008.05.047 18703061
2. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. JC Yao M Hassan A Phan C Dagohoy C Leary JE Mares EK Abdalla JB Fleming JN Vauthey A Rashid DB Evans, J Clin Oncol 2008 26 3063 3072 10.1200/JCO.2007.15.4377 18565894
3. Molecular pathology of the MEN1 gene. SK Agarwal BA Lee KE Sukhodolets PA Kennedy VH Obungu AB Hickman ME Mullendore I Whitten MC Skarulis WF Simonds, (Pubitemid 38594805)
4. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. G Kloppel A Perren PU Heitz, Ann N Y Acad Sci 2004 1014 13 27 10.1196/annals.1294.002 15153416 (Pubitemid 38594787)
5. Endocrine tumors of the gut and pancreas tumor biology and classification. G Rindi G Kloppel, Neuroendocrinology 2004 80 Suppl 1 12 15 15477709 (Pubitemid 39382361)
6. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. DS Klimstra IR Modlin NV Adsay R Chetty V Deshpande M Gonen RT Jensen M Kidd MH Kulke RV Lloyd C Moran SF Moss K Oberg D O'Toole G Rindi ME Robert S Suster LH Tang CY Tzen MK Washington B Wiedenmann J Yao, Am J Surg Pathol 2010 34 300 313 10.1097/PAS.0b013e3181ce1447 20118772
7. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. DS Klimstra IR Modlin D Coppola RV Lloyd S Suster, Pancreas 2010 39 707 712 10.1097/MPA.0b013e3181ec124e 20664470
8. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. G Rindi G Kloppel H Alhman M Caplin A Couvelard WW de Herder B Erikssson A Falchetti M Falconi P Komminoth M Korner JM Lopes AM McNicol O Nilsson A Perren A Scarpa JY Scoazec B Wiedenmann All of the Frascati concencus conference participants European Neuroendocrine Tumour Society (ENTS), Virchows Arch 2006 449 395 401 10.1007/s00428-006-0250-1 16967267 (Pubitemid 44451313)
9. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. G Rindi G Kloppel A Couvelard P Komminoth M Korner JM Lopes AM McNicol O Nilsson A Perren A Scarpa JY Scoazec B Wiedenmann, Virchows Arch 2007 451 757 762 10.1007/s00428-007-0452-1 17674042 (Pubitemid 47497934)
10. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. SB Edge CC Compton, Ann Surg Oncol 2010 17 1471 1474 10.1245/s10434-010-0985-4 20180029
11. Adenoma of islet cells with hyperinsulinism: a review. AO Whipple VK Frantz, Ann Surg 1935 101 1299 1335 10.1097/00000658-193506000-00001 17856569
12. Diazoxide in the management of patients with insulinoma. PN Goode JR Farndon J Anderson ID Johnston JA Morte, World J Surg 1986 10 586 592 10.1007/BF01655532 3019020 (Pubitemid 16096415)
13. Glycemic control in patients with insulinoma treated with everolimus. MH Kulke EK Bergsland JC Yao, N Engl J Med 2009 360 195 197 10.1056/NEJMc0806740 19129539
14. Interactions between zinc, essential fatty acids and prostaglandins: relevance to acrodermatitis enteropathica, total parenteral nutrition, the glucagonoma syndrome, diabetes, anorexia nervosa and sickle cell anaemia. DF Horrobin SC Cunnane, Med Hypotheses 1980 6 277 296 10.1016/0306-9877(80)90125-5 6253772 (Pubitemid 10057424)
15. Free amino acid levels in muscle and liver of a patient with glucagonoma syndrome. E Roth F Muhlbacher J Karner G Hamilton J Funovics, Metabolism 1987 36 7 13 10.1016/0026-0495(87)90055-2 3025552 (Pubitemid 17025305)
16. Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection. Report of three cases. RZ El C Partensky PJ Valette F Berger JA Chayvialle, Eur J Surg Oncol 1998 24 562 567 10.1016/S0748-7983(98)93716-7 9870735 (Pubitemid 28566905)
17. The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth. F Jockenhovel S Lederbogen T Olbricht H Schmidt-Gayk EP Krenning SW Lamberts D Reinwein, Clin Investig 1994 72 127 133 8186658 (Pubitemid 24070381)
18. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. RM Zollinger EH Ellison, Ann Surg 1955 142 709 723 10.1097/00000658-195510000-00015 13259432
19. Gastrointestinal endocrine tumours. Gastrinoma. RT Jensen, Baillieres Clin Gastroenterol 1996 10 603 643 10.1016/S0950-3528(96)90016-0 9113315
20. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists. CB Lambers T Lind S Moberg JB Jansen L Olbe, N Engl J Med 1984 310 758 761 10.1056/NEJM198403223101205 6142418
21. Use of omeprazole in patients with Zollinger-Ellison syndrome. H Frucht PN Maton RT Jensen, Dig Dis Sci 1991 36 394 404 10.1007/BF01298865 2007355
22. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. H Shojamanesh F Gibril A Louie JV Ojeaburu S Bashir A bou-Saif RT Jensen, Cancer 2002 94 331 343 10.1002/cncr.10195 11900219 (Pubitemid 34081361)
23. Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. JV Verner AB Morrison, Am J Med 1958 25 374 380 10.1016/0002-9343(58)90075-5 13571250
24. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. ME Kraenzlin JL Ch'ng SM Wood DH Carr SR Bloom, Gastroenterology 1985 88 185 187 2856877 (Pubitemid 15177661)
25. Biochemistry of neuroendocrine tumours. WW de Herder, Best Pract Res Clin Endocrinol Metab 2007 21 33 41 10.1016/j.beem.2006.12.002 17382264
26. Endocrine tumours of the pancreas. K Oberg B Eriksson, Best Pract Res Clin Gastroenterol 2005 19 753 781 10.1016/j.bpg.2005.06.002 16253899 (Pubitemid 41614122)
27. Circulating markers for endocrine tumours of the gastroenteropancreatic tract. JE Ardill, Ann Clin Biochem 2008 45 539 559 10.1258/acb.2008.008039 18941127
28. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. K Oberg L Kvols M Caplin FG Delle HW de G Rindi P Ruszniewski EA Woltering B Wiedenmann, Ann Oncol 2004 15 966 973 10.1093/annonc/mdh216 15151956 (Pubitemid 39004355)
29. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. PH Kann E Balakina D Ivan DK Bartsch S Meyer KJ Klose T Behr P Langer, Endocr Relat Cancer 2006 13 1195 1202 10.1677/erc.1.01220 17158764 (Pubitemid 46212573)
30. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. ET Janson L Holmberg M Stridsberg B Eriksson E Theodorsson E Wilander K Oberg, Ann Oncol 1997 8 685 690 10.1023/A:1008215730767 9296223 (Pubitemid 27372168)
31. Surgery increases survival in patients with gastrinoma. JA Norton DL Fraker HR Alexander F Gibril DJ Liewehr DJ Venzon RT Jensen, Ann Surg 2006 244 410 419 16926567
32. Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. DL Fraker JA Norton HR Alexander DJ Venzon RT Jensen, Ann Surg 1994 220 320 328 10.1097/00000658-199409000-00008 7916560
33. Functioning insulinoma - incidence, recurrence, and long-term survival of patients: a 60-year study. FJ Service MM McMahon PC O'Brien DJ Ballard, Mayo Clin Proc 1991 66 711 719 1677058
34. Surgical management of insulinoma associated with multiple endocrine neoplasia type I. DS O'Riordain T O'Brien JA van Heerden FJ Service CS Grant, World J Surg 1994 18 488 493 10.1007/BF00353743 7725733
35. Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. MJ Demeure DC Klonoff JH Karam QY Duh OH Clark, Surgery 1991 110 998 1004 1684067
36. Hepatic surgery for metastases from neuroendocrine tumors. JM Sarmiento FG Que, Surg Oncol Clin N Am 2003 12 231 242 10.1016/S1055-3207(02)00076-5 12735141 (Pubitemid 36210867)
37. Hepatic resection for metastatic neuroendocrine carcinomas. FG Que DM Nagorney KP Batts LJ Linz LK Kvols, Am J Surg 1995 169 36 42 10.1016/S0002-9610(99)80107-X 7817996
38. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. JM Sarmiento G Heywood J Rubin DM Ilstrup DM Nagorney FG Que, J Am Coll Surg 2003 197 29 37 10.1016/S1072-7515(03)00230-8 12831921 (Pubitemid 36759176)
39. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. B Dousset O Saint-Marc J Pitre O Soubrane D Houssin Y Chapuis, World J Surg 1996 20 908 914 10.1007/s002689900138 8678970
40. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. T Steinmuller R Kianmanesh M Falconi A Scarpa B Taal DJ Kwekkeboom JM Lopes A Perren G Nikou GF Delle Fave D O'Toole Frascati Concensus Conference Participants, Neuroendocrinology 2008 87 47 62 10.1159/000111037 18097131 (Pubitemid 350308294)
41. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. C Toumpanakis T Meyer ME Caplin, Best Pract Res Clin Endocrinol Metab 2007 21 131 144 10.1016/j.beem.2007.01.005 17382269 (Pubitemid 46421904)
42. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. D O'Toole P Ruszniewski, Best Pract Res Clin Gastroenterol 2005 19 585 594 10.1016/j.bpg.2005.02.011 16183529 (Pubitemid 41447720)
43. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. S Gupta JC Yao K Ahrar MJ Wallace FA Morello DC Madoff R Murthy ME Hicks JA Ajani, Cancer J 2003 9 261 267 10.1097/00130404-200307000-00008 12967136
44. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. PJ Mazzaglia E Berber M Milas AE Siperstein, Surgery 2007 142 10 19 10.1016/j.surg.2007.01.036 17629995 (Pubitemid 47042092)
45. Radiofrequency ablation of neuroendocrine liver metastases. A Elvin B Skogseid P Hellman, Abdom Imaging 2005 30 427 434 10.1007/s00261-004-0257-5 15791486 (Pubitemid 41176120)
46. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. CG Moertel M Lefkopoulo S Lipsitz RG Hahn D Klaassen, N Engl J Med 1992 326 519 523 10.1056/ NEJM199202203260804 1310159
47. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. MA Kouvaraki JA Ajani P Hoff R Wolff DB Evans R Lozano JC Yao, J Clin Oncol 2004 22 4762 4771 10.1200/JCO.2004.04.024 15570077
48. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. S Ekeblad A Sundin ET Janson S Welin D Granberg H Kindmark K Dunder G Kozlovacki H Orlefors M Sigurd K Obergo B Erriksson B Skogseid, Clin Cancer Res 2007 13 2986 2991 10.1158/1078-0432.CCR-06-2053 17505000 (Pubitemid 46849574)
49. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. MH Kulke JL Hornick C Frauenhoffer S Hooshmand DP Ryan PC Enzinger JA Meyerhardt JW Clark K Stuart CS Fuchs MS Redston, Clin Cancer Res 2009 15 338 345 10.1158/1078-0432. CCR-08-1476 19118063
50. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. JR Strosberg RL Fine J Choi A Nasir D Coppola DT Chen J Helm L Kvols, Cancer 2011 117 268 275 10.1002/cncr.25425 20824724
51. A phase II study of temozolomide and bevacizumab in patients with advance neuroendocrine tumors [abstract]. MH Kulke K Stuart C Earle, ASCO Annual Meeting Proc 2006 24 4044a
52. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. MH Kulke K Stuart PC Enzinger DP Ryan JW Clark A Muzikansky M Vincitore A Michelini CS Fuchs, J Clin Oncol 2006 24 401 406 10.1200/JCO.2005.03.6046 16421420 (Pubitemid 46630459)
53. Phase I/II study of everolimus (RAD001) in combination with temozolomide in patients with advanced pancreatic neuroendocrine tumors [abstract]. MH Kulke L Blaszkowsky A Zhu, Gastrointestinal Cancers Symposium 2010 223a
54. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. WA Breeman JM de DJ Kwekkeboom R Valkema WH Bakker PP Kooij TJ Visser EP Krenning, Eur J Nucl Med 2001 28 1421 1429 10.1007/s002590100502 11585303
55. Peptide receptor radionuclide therapy. JJ Teunissen DJ Kwekkeboom JM de JP Esser R Valkema EP Krenning Endocrine tumours of the gastrointestinal tract, Best Pract Res Clin Gastroenterol 2005 19 595 616 10.1016/j.bpg.2005.04.001 16183530 (Pubitemid 41447721)
56. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. DJ Kwekkeboom WW de Herder BL Kam CH van Eijck EM van PP Kooij RA Feelders MO van Aken EP Krenning, J Clin Oncol 2008 26 2124 2130 10.1200/JCO.2007.15.2553 18445841
57. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. DL Bushnell TM O'Dorisio MS O'Dorisio Y Menda RJ Hicks CE Van JL Baulieu F Borson-Chazot L Anthony AB Benson K Oberg AB Grossman M Connolly H Bouterfa Y Li KA Kacena N LaFrance SA Pauwels, J Clin Oncol 2010 28 1652 1659 10.1200/JCO.2009.22.8585 20194865
58. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide in advanced low-grade neuroendocrine carcinoma [abstract]. A Phan J Yao D Fogelman, J Clin Oncol 2010 28
59. MC044h, a phase II trial of sorafenib in patients with metastatic neuroendocine tumors: a phase II consortium study [abstract]. TJ Hobday J Rubin K Holen J Picus R Donehower R Marschke W Maples R Lloyd M Mahoney C Erlichman, ASCO Annual Meeting Proc 2007 25 4505a
60. Activity of sunitinib in patients with advanced neuroendocrine tumors. MH Kulke HJ Lenz NJ Meropol J Posey DP Ryan J Picus E Bergsland K Stuart L Tye X Huang ZJ Li CM Baum CS Fuchs, J Clin Oncol 2008 26 3403 3410 10.1200/JCO.2007.15.9020 18612155
61. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. E Raymond L Dahan JL Raoul YJ Bang I Borbath C Lombard-Bohas J Valle P Metrakos D Smith A Vinik JS Chen D Horsch P Hammel B Wiedenmann E Van Cutsem S Patyna DR Lu C Blanckmeister R Chao P Ruszniewski, N Engl J Med 2011 364 501 513 10.1056/NEJMoa1003825 21306237
62. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. I Duran J Kortmansky D Singh H Hirte W Kocha G Goss L Le A Oza T Nicklee J Ho D Birle GR Pond D Arboine J Dancey S Aviel-Ronan MS Tsao D Hedley LL Siu, Br J Cancer 2006 95 1148 1154 10.1038/sj.bjc.6603419 17031397 (Pubitemid 44660065)
63. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. JC Yao AT Phan DZ Chang RA Wolff K Hess S Gupta C Jacobs JE Mares AN Landgraf F Merci-Bernstam, J Clin Oncol 2008 26 4311 4318 10.1200/JCO.2008.16.7858 18779618
64. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. JC Yao C Lombard-Bohas E Baudin LK Kvols P Rougier P Ruszniewski S Hoosen PJ St T Haas D Lebwohl E Van Cutsem MH Kulke TJ Hobday TM O'Dorisio MH Shah G Cadiot G Luppi JA Posey B Wiedenmann, J Clin Oncol 2010 28 69 76 10.1200/JCO.2009.24. 2669 19933912
65. Everolimus for advanced pancreatic neuroendocrine tumors. JC Yao MH Shah T Ito CL Bohas EM Wolin CE Van TJ Hobday T Okusaka J Capdevila EG de Vries P Tomassetti ME Pavel S Hoosen T Haas J Lincy D Lebwohl K Oberg RAD001 in Advanced Neuroendocrine Tumors Third Trial (RADIANT-3) Study Group, N Engl J Med 2011 364 514 523 10.1056/NEJMoa1009290 21306238
66. Randominzed run-in study of bevacizumab and everolimus in low to intermediate grade neuroendocrine tumors using perfusion CT as a functional biomarker [abstract]. J Yao A Phan D Fogelman, J Clin Oncol 2011 28
67. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. RK Ramanathan A Cnaan RG Hahn PP Carbone DG Haller, Ann Oncol 2001 12 1139 1143 10.1023/A:1011632713360 11583197 (Pubitemid 32834496)